Kaster Technologies Inc.

Based in Canada, Kaster Technologies provides innovative software solutions tailored for the pharmaceutical manufacturing sector, enhancing production efficiency through advanced AI technology. Kaster Technologies, founded in 2022, operates from Montreal, Canada, specializing in software for pharmaceutical production planning. The company has completed 1 deal and raised CAD 1. 6 million in funding led by Graphite Ventures, with participation from Hidden Layers Capital.

This funding will support software refinement and expanding the client base. The founder has not been disclosed, and the company does not have known subsidiaries. Kaster Technologies specializes in innovative short-term production planning software specifically designed for pharmaceutical manufacturers. Their flagship product, AIM | Pace™, utilizes proprietary prescriptive AI to enhance the efficiency of complex drug manufacturing processes.

This software addresses common challenges such as optimizing large-scale drug production, synchronizing laboratory testing and quality control with production schedules, and removing inefficiencies that lead to delays. AIM | Pace™ has been validated at sites such as one of Canada’s largest sterile injectable facilities, demonstrating its capacity to deliver more than 10% additional production capacity without the need for new equipment. The company serves a diverse client base in the pharmaceutical sector, including manufacturers of sterile injectables, oral solid dosage (OSD) forms, and biologics, primarily in North America and Europe. Kaster Technologies generates revenue through a subscription-based model for its software solutions, particularly AIM | Pace™.

Clients typically engage with the company on a contractual basis, which includes services such as configuration, testing, and ongoing support. The transactional structure involves partnerships with pharmaceutical manufacturers that utilize the software to improve production efficiency and compliance with Good Manufacturing Practices (GMP). Given the complex nature of pharmaceutical production, clients benefit from tailored implementations that address specific operational bottlenecks, ensuring continuous alignment between production workflows and quality assurance processes. The revenue model is inherently designed to foster long-term partnerships where continuous innovation and feature development occur in collaboration with client teams.

In February 2026, Kaster Technologies raised CAD 1. 6 million in pre-seed funding led by Graphite Ventures, with participation from Hidden Layers Capital and individual investors. The company plans to utilize this funding to refine its software, increase sales to new drug manufacturers, and hire additional employees to support growth. Kaster Technologies aims to expand its reach into new markets, focusing on North America and Europe, with specific initiatives planned for rollout over the next year.